Screener
Generate Biomedicines, Inc. GENB Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Generate Biomedicines, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 6:01 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Contributions from non-controlling interests | 7,500 | 750 |
| Proceeds from exercise of stock options | 3,217 | 483 |
| Payments on finance lease obligations | (1,115) | (2,646) |
| Net cash provided by financing activities | 378,891 | 20,560 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 38,569 | 42,916 |
| Cash, cash equivalents and restricted cash at beginning of period | 126,038 | 181,831 |
| Cash, cash equivalents and restricted cash at end of period | $164,607 | $224,747 |
| Cash and cash equivalents, end of period | 160,575 | 220,607 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Generate Biomedicines, Inc.'s financing cash flow?
- Generate Biomedicines, Inc. (GENB) reported financing cash flow of $378.89M in Q1 2026.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Generate Biomedicines, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude